N/A
N=130
Cataract Surgery: Femto LDV Z8 Versus Conventional
Cataract
Bottom Line
View on ClinicalTrials.gov: NCT02351271 ↗Enrolled (actual)
130
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Effective Phaco Time (EPT) — 1.48; 2.3 EPT
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Femto LDV Z8 (Device); Manual capsulorhexis&lens fragmentation (Device)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Ziemer Ophthalmic Systems AG
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effective Phaco Time (EPT) |
1.48; 2.3 | — |
| SECONDARY Ease of Phacoemulsification |
66; 59; 2; 3 | — |
| SECONDARY Number of Participants With Complete Treatment Pattern |
68; 62 | — |
Summary
The aim of the study is to demonstrate the performance and safety of the Femtosecond laser-assisted anterior capsulotomy and lens fragmentation on human eyes using the FEMTO LDV Z8 compared to conventional technique in cataract surgery.
Eligibility Criteria
Inclusion Criteria
- Eligible to undergo cataract extraction by phacoemulsification with primary intraocular lens Implantation
- Able to co-operate with the docking system for the femtosecond laser
- Clear corneal media
- 50 years of age or older
- Willing and able to return for scheduled follow-up examinations
Exclusion Criteria
- Minimal and maximal K-values of the central 3mm zone that differ by more than 5D on a keratometric map of the cornea
- Maximum K-value that exceeds 58D
- Minimal K-value of less than 37D
- Corneal disease or pathology, such as corneal scaring or opacity, that precludes transmission of laser wavelength or that distorts laser light
- Poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally
- Manifest Glaucoma+OHT (ocular hypertension), pseudoexfoliation
- Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye
- Known sensitivity to planned concomitant medications
- History of lens or zonular instability
- Keratoconus or keratectasia
- Immune compromised or diagnosis of connective tissue disease, clinically sign. atopic disease, insulin dependent diabetes mellitus, autoimmune diseases, ocular herpes zoster or simplex, endocrine diseases, lupus, RA, collagenosis and other acute or chronic illnesses that increases the risk to the subject or confounds the outcomes of this study, in the opinion of the study PI.
- Anterior chamber depth (ACD) 4.8 mm as measured from the corneal endothelium.
- Extensive corneal scarring
- Developmental disability or cognitive impairment (would preclude adequate comprehension of the Informed Consent (IC) form and/or the ability to record the study measurements)
- Concurrent participation in another ophthalmological clinical study
Data sourced from ClinicalTrials.gov (NCT02351271). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.